Cargando…
Azvudine versus Paxlovid for oral treatment of COVID-19 in Chinese patients with pre-existing comorbidities
Autores principales: | Dian, Yating, Meng, Yu, Sun, Yuming, Deng, Guangtong, Zeng, Furong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The British Infection Association. Published by Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10188372/ https://www.ncbi.nlm.nih.gov/pubmed/37207823 http://dx.doi.org/10.1016/j.jinf.2023.05.012 |
Ejemplares similares
-
Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study
por: Sun, Yuming, et al.
Publicado: (2023) -
Corrigendum to ‘Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.’ [EClinicalMedicine 59 (2023) 101981]
por: Sun, Yuming, et al.
Publicado: (2023) -
Elevated troponin levels predict the reduced efficacy of Paxlovid in COVID-19 patients
por: Zhao, Deze, et al.
Publicado: (2023) -
Lactate dehydrogenase predicts disease progression outcome in COVID-19 patients treated with Azvudine
por: Mao, Manyun, et al.
Publicado: (2023) -
The first Chinese oral anti-COVID-19 drug Azvudine launched
por: Yu, Bin, et al.
Publicado: (2022)